Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.

@article{Nakamura2013SubunitdependentIA,
  title={Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.},
  author={Yukiko Nakamura and Yusuke Ishida and Takahiro Yamada and Makoto Kondo and Shoichi Shimada},
  journal={Journal of neurochemistry},
  year={2013},
  volume={125 1},
  pages={7-15}
}
The 5-hydroxytryptamine (serotonin, 5-HT) type 3 (5-HT3) receptor belongs to the superfamily of Cys-loop ligand-gated ion channels, and can be either homopentameric (5-HT3A) or heteropentameric (5-HT3AB) receptor. Several modulators are known, which either inhibit or potentiate this channel, but few have any appreciable selectivity between the two subtypes or can modulate one receptor differently to the other. In this study, we show that the anticancer drug, topotecan, bidirectionally modulates… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Similar Papers

Loading similar papers…